Armata Pharmaceuticals, Inc. - 8-K Filing
Armata Pharmaceuticals receives $3.7 million in non-dilutive funding from the U.S. Department of War for Phase 3 development of AP-SA02, bringing total DoW support to $32.4 million. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ARMP